drugset / Trial / NCT05156060

Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

NCT05156060

Phase 1/2 Recruiting 64 enrolled Natalie Lockney
NaSingle-groupOpen-labelTreatment

Summary

This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.

Timeline

Start
2022-01-24
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Small molecule Oral
Subject Ketamine Small molecule 40 mg Intranasal